Our Doctors
- Home
- Nuclear Medicine Theranostics
- Our Doctors
Dr Damian Khor Lih Kin
MMED (Radiology), FAMS,
Diplomate Certification Board of Nuclear Cardiology
Biography:
Dr Khor obtained his basic medical degree from the National University of Singapore, following which he obtained his postgraduate qualification (FRCR) in 2011. He is the first dual accredited Nuclear Medicine and Diagnostic Radiologist in Singapore.
Dr Khor was formerly a consultant at the National Cancer Institute of Singapore and Department of Diagnostic Imaging, NUHS, where he was involved in numerous research work and has published in many peer review journals. He currently sits on the MOH advisory committee for Nuclear Medicine practice and is a National Examiner for post-graduate training in Diagnostic Radiology in Singapore.
Dr Khor has trained at the Peter MacCallum cancer centre and The Austin Hospital in Melbourne in the field of Nuclear Medicine Theranostics and PET neuroimaging. He has special interests in Oncologic PET imaging, PET Neuroimaging and targeted radionuclide therapy.
Specialty Interests:
- Oncologic PET imaging
- PET neuroimaging
- Targeted radionuclide therapy
- Theranostics
Professional Memberships:
Member, Singapore Medical Association
Execute Committee, Singapore Radiological Society
Fellow, Royal College of Radiologist (UK)
Fellow, Academy of Medicine Singapore
Dr Sidney Yu
The Fellowship of the Royal Society of Chemistry (FRSC) is one of the most prestigious awards conferred by the Royal Society of Chemistry (RSC) in
the United Kingdom. Existing Fellows include award winning scientists and Nobel prize winners.
Dr Sidney has been instrumental in the development of radiochemistry and nuclear medicine in Singapore and Southeast Asia. A senior and highly respected radiochemist, he established Singapore’s first GMP-compliant cyclotron and radiochemistry laboratory, attracting major investments from multinational pharmaceutical companies such as Roche, Bayer, and Merck. He has driven key advances in targeted radionuclide therapies,
including Selective Internal Radiation Therapy (SIRT), the first radiochemo-embolization therapy for unresectable liver cancer, and the introduction of Peptide Receptor Radionuclide Therapy (PRRT). Since joining SAM in 2018 as Director of Radiopharmaceuticals, Dr Sidney has built the radiopharmaceutical laboratory from the ground up, led the introduction of novel radiotracers with strong clinical potential—including N-13 ammonia and Ac-225 PSMA—and positioned SAM as one of the few centres in Southeast Asia capable of producing short half-life radiotracers and serving as a trusted clinical research partner for global theranostics development.
Heartiest congratulations Dr Sidney from
management, doctors and staff of Singapore Institute of Advanced Medicine
Holdings.
